ORCID Profile
0000-0002-7667-8868
Current Organisations
Kwazulu-Natal Museum
,
Turning Point Alcohol and Drug Centre
,
Monash University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: SAGE Publications
Date: 16-01-2018
Abstract: Chronic meth hetamine use is commonly associated with the development of psychotic symptoms. The predictors and correlates of meth hetamine-associated psychosis are poorly understood. We sought to systematically review factors associated with psychotic symptoms in adults using illicit hetamine or meth hetamine. A systematic literature search was performed on MEDLINE (OVID), PsycINFO and EMBASE databases from inception to 8 December 2016. The search strategy combined three concept areas: meth hetamine or hetamine, psychosis and risk factors. Included studies needed to compare adults using illicit meth hetamine or hetamine, using a validated measure of psychosis, on a range of risk factors. Of 402 identified articles, we removed 45 duplicates, 320 articles based on abstract/title and 17 ineligible full-text articles, leaving 20 included studies that were conducted in 13 populations. Two co-authors independently extracted the following data from each study: country, setting and design participant demographic and clinical details s le size measure/s used and measures of association between psychosis outcomes and risk factors. In idual study quality was assessed using a modified Newcastle-Ottawa Scale, and strength of evidence was assessed using GRADE criteria. Frequency of meth hetamine use and severity of meth hetamine dependence were consistently found to be associated with psychosis, and sociodemographic factors were not. There was inconsistent evidence available for all other risk factors. In idual study quality was low–moderate for the majority of studies. Heterogeneity in study outcomes precluded quantitative synthesis of outcomes across studies. The most consistent correlates of psychotic symptoms were increased frequency of meth hetamine use and dependence on meth hetamine. The findings of this review highlight the need for targeted assessment and treatment of meth hetamine use in in iduals presenting with psychosis.
Publisher: Elsevier BV
Date: 06-2020
Publisher: SAGE Publications
Date: 02-07-2022
Publisher: Wiley
Date: 10-08-2021
DOI: 10.1111/ADB.13079
Abstract: Stimulant use disorder is associated with significant global health burden. Despite evidence for sex differences in the development and maintenance of stimulant use disorder, few studies have focused on mechanisms underpinning distinct trajectories in females versus males, including the effect of the ovarian sex hormones estrogen and progesterone. This review aimed to identify and synthesise the existing preclinical and clinical literature on the effect of ovarian sex hormones on stimulant consumption in females. A systematic search of peer‐reviewed literature identified 1593 articles, screened using the following inclusion criteria: (1) adult female humans or animals, (2) using stimulant drugs, (3) ovarian sex hormones were administered exogenously OR were measured in a validated manner and (4) with stimulant consumption as an outcome measure. A total of 50 studies (3 clinical and 47 preclinical) met inclusion criteria. High‐estrogen (low progesterone) phases of the menstrual/estrus cycle were associated with increased stimulant use in preclinical studies, while there were no clinical studies examining estrogen and stimulant consumption. Consistent preclinical evidence supported progesterone use reducing stimulant consumption, which was also identified in one clinical study. The review was limited by inconsistent data reporting across studies and different protocols across preclinical laboratory paradigms. Importantly, almost all studies examined cocaine use, with impact on meth hetamine use a significant gap in the existing evidence. Given the safety and tolerability profile of progesterone, further research is urgently needed to address this gap, to explore the potential therapeutic utility of progesterone as a treatment for stimulant use disorder.
Publisher: Wiley
Date: 03-07-2023
DOI: 10.1111/DAR.13703
Abstract: Youth drinking rates have declined over the past 15 years while self‐reported psychological distress has increased, despite a well‐recognised positive relationship between the two. The current study aimed to identify changes in the relationship between psychological distress and alcohol use in adolescents from 2007 to 2019. This study used survey responses from 6543 Australians aged 14–19 years who completed the National Drug Strategy Household Survey in 2007, 2010, 2013, 2016 or 2019. Logistic and multivariable linear regressions with interactions (psychological distress × survey wave) predicted any alcohol consumption, short‐term risk and average quantity of standard drinks consumed per day. Psychological distress was a positive predictor of alcohol use and this association remained stable across survey waves as alcohol consumption decreased. The relationship between distress and alcohol consumption remained relatively steady, even as youth drinking declined and distress increased. The proportion of drinkers experiencing distress did not increase as consumption rates dropped, suggesting that the decline in youth drinking is occurring independently of the increase in self‐reported and diagnosed mental health issues.
Publisher: AMPCo
Date: 22-11-2018
DOI: 10.5694/MJA2.12036
Abstract: To compare changes in pregabalin prescribing and misuse-related ambulance attendances to characterise the patients attended by paramedics for pregabalin misuse-related harms to assess the association of pregabalin misuse with use of other sedatives and with suicidal ideation and self-harm to compare the characteristics of pregabalin misuse-related harms in people who misuse pregabalin according to whether or not they also used other sedatives. Retrospective analysis of data on ambulance attendances in Victoria, January 2012 - December 2017, for which pregabalin misuse-related harms were a contributing factor. Rates of pregabalin misuse-related ambulance attendances, pregabalin prescription rates (each 6-monthly) patient characteristics, including age, sex, history of drug misuse or psychiatric problems, concurrent use of other sedatives, and current suicidal ideation and self-harm. There were 1201 pregabalin misuse-related attendances during the study period the rate increased from 0.28 cases per 100 000 population in the first half of 2012 to 3.32 cases per 100 000 in the second half of 2017. The attendance rate was strongly correlated with prescription rates in Australia (r = 0.90 P = 0.001). 593 attendances (49%) were for people with a history that may have contraindicated prescribing pregabalin. Pregabalin was frequently misused with other sedatives (812 attendances, 68%), particularly benzodiazepines (440, 37%) 472 attendances (39%) were associated with suicide attempts. People who misused pregabalin with other sedatives more frequently presented with moderate to severe impairments of consciousness, but the frequency of suicide attempts was similar whether other sedatives were concurrently used or not. Rates of pregabalin misuse-related ambulance attendances in Victoria have increased markedly over the past 6 years. Caution is required when prescribing pregabalin for people taking other sedatives. Limiting the dispensing of this drug may reduce the risks associated with its misuse.
Publisher: Wiley
Date: 30-05-2023
DOI: 10.1111/ADD.16230
Abstract: To determine whether the risk of psychotic symptoms during weeks of meth hetamine use was dependent on, increased by, or independent of having a family history of psychosis. Secondary analysis of 13 contiguous 1‐week periods of data (1370 weeks). A risk modification framework was used to test each scenario. Geelong, Wollongong and Melbourne, Australia. Participants in a randomized controlled trial of treatment for meth hetamine dependence ( n = 148) who did not have a primary psychotic disorder on enrolment. Psychotic symptoms in the previous week were defined as a score of 3+ on any of the Brief Psychiatric Rating Scale items of hallucinations, unusual thought content or suspiciousness. Any (vs no) meth hetamine use in the previous week was assessed using the Timeline Followback method. Self‐reported family history of psychosis was assessed using the Diagnostic Interview for Psychosis. The risk of psychotic symptoms in the past week was independently associated with meth hetamine use in that week (relative risk [RR] = 2.3, 95% CI = 1.3–4.3) and with having a family history of psychosis (RR = 2.4, 95% CI = 0.9–7.0) the joint risk among participants with a family history of psychosis during weeks when they were using meth hetamine was large (RR = 4.0, 95% CI = 2.0–7.9). There was no significant interaction between a family history of psychosis and meth hetamine use in predicting psychotic symptoms (interaction RR = 0.7 95% CI = 0.3–1.8), but there was a small non‐significant excess risk due to the interaction (0.20 95% CI = −1.63 to 2.03). Among people dependent on meth hetamine, the relative risk of psychotic symptoms during weeks of meth hetamine use does not appear to be dependent on, or increased by, having a family history of psychosis. However, a family history of psychosis does appear to be an independent risk factor that contributes to the absolute risk of psychotic symptoms in this population.
Publisher: Wiley
Date: 03-2020
DOI: 10.1111/DAR.13029
Publisher: Frontiers Media SA
Date: 13-12-2019
Publisher: SAGE Publications
Date: 02-2014
Publisher: Elsevier BV
Date: 10-2071
Publisher: Springer Science and Business Media LLC
Date: 21-05-2018
Publisher: SAGE Publications
Date: 10-01-2017
Abstract: Few people who use stimulants seek clinical treatment. This study sought to describe a cohort of stimulant users who attended a stimulant-specific treatment service, Access Point, in Melbourne, Australia between 2008 and 2014. A retrospective audit of the records of adults ( n = 175) who sought treatment for stimulant use at a stimulant-specific outpatient treatment service was conducted. Service users had a median age of 32 (range = 19–54). Most stimulant users were in part- or full-time employment (53.6%) and had stable accommodation (85%). There was a high rate of mental health comorbidity, with over half (52%) reporting a previous history of mental health problems, while one-third (33%) reported previous suicide attempts. There was a high rate (48%) of previous meth hetamine-associated psychosis, which was significantly correlated with frequency of use ( x 2 = 13.698, p = 0.008). This study supports the potential of a targeted and specialised treatment service as a means of early intervention for stimulant users. The high prevalence of meth hetamine-associated psychosis history in this group suggests that frequent use of stimulants increases the risk of psychosis, even among high-functioning in iduals.
Publisher: Elsevier BV
Date: 2023
Publisher: Springer Singapore
Date: 2016
Publisher: Elsevier BV
Date: 11-2023
Publisher: Cold Spring Harbor Laboratory
Date: 21-07-2020
DOI: 10.1101/2020.07.16.20155341
Abstract: COVID-19 has infected more than 13 million people worldwide and impacted the lives of many more, with a particularly devastating impact on vulnerable populations, including people with substance use disorders (SUDs). Quarantines, travel bans, regulatory changes, social distancing and ‘lockdown’ measures have affected drug and alcohol supply chains and subsequently their availability, price and use patterns, with possible downstream effects on presentations of SUDs and demand for treatment. Given the lack of multicentric epidemiologic studies, we conducted a rapid global survey within the International Society of Addiction Medicine (ISAM) network in order to understand the status of substance-use patterns during the current pandemic. Cross-sectional survey. Worldwide. Starting on April 4 th , 2020 during a 5-week period, the survey received 185 responses from 77 countries. To assess addiction medicine professionals’ perceived changes in drug and alcohol supply, price, use pattern and related complications during the COVID-19 pandemic. Participants reported (among who answered “decreased” or “increased”, percentage of those who were in majority is reported in the parenthesis) a decrease in drug supply (69.0%), and at the same time an increase in price (95.3%) globally. With respect to changes in use patterns, an increase in alcohol (71.7%), cannabis (63.0%), prescription opioids (70.9%), and sedative/hypnotics (84.6%) use was reported while the use of hetamines (59.7%), cocaine (67.5%), and opiates (58.2%) was reported to decrease overall. The global report on changes in the availability, use patterns and complications of alcohol and drugs during the COVID-19 pandemic should be considered in making new policies and in developing mitigating measures and guidelines during the current pandemic (and probable future ones) in order to minimize risks to SUDs. Authors claimed no competing interest
Publisher: SAGE Publications
Date: 22-06-2017
Abstract: Attention deficit hyperactivity disorder and stimulant use disorder commonly co-exist, and appropriate treatments have not been well established. To provide guidance for treatment of co-existing attention deficit hyperactivity disorder and stimulant use disorder. A systematic review of published English articles using MEDLINE, EMBASE, CINAHL, PsycINFO and Cochrane, utilising consistent search terms. Randomised controlled trials, comparing any treatment arm with a control group, for participants meeting Diagnostic and Statistical Manual of Mental Disorders or equivalent criteria for both attention deficit hyperactivity disorder and stimulant use disorder. Eight trials were identified for inclusion in this review. Four of eight studies showed improvement in attention deficit hyperactivity disorder outcome measures compared with placebo. Two of six studies that reported substance use outcomes showed improvement in treatment arms compared with placebo. Studies to show effect tended to be those with the highest treatment dosage. Evidence for the efficacy of treatment of patients with comorbid stimulant use disorder and attention deficit hyperactivity disorder is limited. Promising outcomes need replication in further studies utilising higher treatment dosage.
Publisher: Elsevier BV
Date: 11-2019
Publisher: Wiley
Date: 22-11-2020
DOI: 10.1111/ADD.14848
Abstract: Although the prevalence of gamma-hydroxybutyrate (GHB) use is relatively low globally, harms related to the drug appear to be increasing. Few existing studies present reliable, representative, population-level data on GHB-related harms. The aim of this study was to investigate trends in acute GHB-related harms within an ambulance database in Australia. Cross-sectional, retrospective analysis of data on all GHB-related ambulance attendances in the state of Victoria, Australia during a 7-year period (January 2012-December 2018) MEASUREMENTS: Presentations were characterized based on patient demographics, transport to hospital, co-occurring substance use (i.e. GHB only, alcohol, meth hetamine, heroin, benzodiazepine and cannabis) and clinical presentation (e.g. symptoms of anxiety, psychosis, depression). There were 5866 GHB-related ambulance attendances between 2012 and 2018, with the prevalence rate increasing from 8.8 per 100 000 population in 2012 to a maximum of 21.7 per 100 000 population in 2017. Meth hetamine [odds ratio (OR) = 6.23, P < 0.001] and benzodiazepine-related (OR = 1.43, P < 0.001) co-occurrences ages between 18-29 (OR = 6.58, P < 0.001) and 30-39 years (OR = 2.02, P < 0.001) and male gender (OR = 1.23, P < 0.001) were significant predictors of GHB-related attendances. There has been a 147% increase in the prevalence of GHB-related ambulance attendances in Victoria, Australia between 2012 and 2019, largely attributable to a growth in the proportions of people using gamma-hydroxybutyrate alone or concurrently with meth hetamine.
Publisher: Wiley
Date: 05-2023
DOI: 10.1111/DAR.13670
Abstract: Meth hetamine use is a public health concern that has been associated with comorbid mental health problems. We aim to better understand the relationship between meth hetamine use and depression by: (i) systematically reviewing and meta‐analysing the risks of depression by meth hetamine use and (ii) investigating the risk of unmeasured confounding. A systematic review and meta‐analysis were conducted following PRISMA guidelines. EMBASE, PsycINFO and PubMed were searched to identify human studies reporting on the association between meth hetamine or hetamine use and depressive outcomes. The data were summarised narratively and meta‐analysed, stratified by cross‐sectional and longitudinal estimates. Unmeasured confounding was assessed by E ‐values analyses. From the 6606 studies that came up from the search, 14 eligible studies were included in the narrative review and had data for meta‐analysis. A significant association was found between any use of meth hetamine and any depression outcomes in cross‐sectional (odds ratio [OR] = 1.66 [95% confidence interval [CI] 1.34, 2.05]) and longitudinal estimates (OR = 1.18 [95% CI 1.08, 1.28]). People with a meth hetamine use disorder had significantly higher odds of depression than those without (OR = 2.80 [95% CI 1.40, 5.90]). The E ‐values ranged from 1.28 to 6.30 for cross‐sectional studies and from 2.37 to 3.21 for longitudinal studies. Based on limited data, people who used meth hetamine have higher odds of depression than people who do not. There were mostly a low to moderate risk of unmeasured confounding in the longitudinal study results. Future longitudinal studies conducted using causal framework methods are warranted.
Publisher: Elsevier BV
Date: 10-2021
Publisher: Wiley
Date: 19-08-2021
DOI: 10.1111/AJAD.13212
Abstract: Sleep problems are common among clients attending alcohol and drug services, yet the specific components of sleep disturbed by primary drug of concern (PDOC), and their relationships to affective disorder symptoms are unclear. We examined sleep problems in clients ( n = 32) attending a specialist addiction clinic. Global sleep quality was rated poor by % of participants (particularly disturbances, latency and efficiency components), with significant associations ( p .05) between poor sleep quality and depression ( r = .517), anxiety ( r = .571) and stress ( r = .503). Sleep quality was significantly poorer among those with a nonalcohol PDOC compared with alcohol as PDOC, t (22) = 3.09, p = .005. Poor sleep is almost ubiquitous among clients attending alcohol and drug services. However, components of sleep quality disturbed differ in terms of PDOC, highlighting the need for in idualised sleep interventions.
Publisher: Wiley
Date: 29-05-2023
DOI: 10.1111/DAR.13691
Abstract: Contingency management (CM) is currently the most efficacious treatment for meth hetamine use, yet it is rarely available in routine care. We examined the viewpoints of people who use meth hetamine on CM as a potential treatment for meth hetamine use disorder. Semi‐structured qualitative interviews with 30 Australians aged 18 years or older who had used meth hetamine at least weekly in the past 6 months. Participants reported overall positive attitudes towards CM as a potential treatment option for meth hetamine use disorder. However, there was need for greater flexibility in meeting participant treatment goals (e.g., reduced use or complete abstinence), with particular concern about the viability of initiating abstinence, both in terms of the sufficiency of the initial financial incentive and managing withdrawal symptoms. There was strong interest in the use of digital technologies to provide remote CM, particularly around the convenience and flexibility this offered. Despite this, participants remained keen to access adjunctive treatment and support services but stressed that engagement with these additional services should not be mandatory. Marketing of CM will need to address preconceptions about drug‐testing used in abstinence‐based CM being punitive (especially urine testing) and its connotations with criminal justice interventions. Positive attitudes towards CM bode well for potential uptake should CM be made available in routine clinical practice. However, there is a need to adapt CM to ensure it is feasible and attractive to people who are seeking treatment for meth hetamine use disorder.
Publisher: Wiley
Date: 06-08-2023
DOI: 10.5694/MJA2.52060
Publisher: Oxford University Press (OUP)
Date: 10-03-2021
Publisher: AMPCo
Date: 07-08-2021
DOI: 10.5694/MJA2.51213
Publisher: Wiley
Date: 08-11-2021
DOI: 10.5694/MJA2.51334
Publisher: Springer Science and Business Media LLC
Date: 04-06-2019
Publisher: SAGE Publications
Date: 08-2015
Abstract: In iduals with co-occurring substance use and anxiety disorders can present as a diagnostic challenge. This article aims to provide clinicians with an overview of practical approaches to assessment and treatment of this common co-morbidity. A comprehensive assessment can assist in formulating a holistic management plan that incorporates adapted psychological and pharmacological therapies to address both substance use and anxiety disorders in an integrated manner.
Publisher: Psychology Press
Date: 14-04-0384
Publisher: Wiley
Date: 09-07-2018
DOI: 10.1111/DAR.12841
Abstract: Prescribed psychotropic medications contribute to overdose mortality among people with alcohol and other drug (AOD) disorders. We report on prescribed psychotropic medication use among AOD treatment service attendees, focusing on sedative drugs. Prospective multi-site naturalistic outcome study in residential and outpatient AOD treatment facilities in Victoria and Western Australia. A convenience s le of 480 people (57% male mean age 36.1) entering treatment were surveyed, of whom 313 (65%) were followed up by telephone interview after a median of 377 days. Participants' prescribed psychotropic medication use was ascertained by self-report at baseline and follow-up. At baseline, 41% of participants reported prescribed sedative medication (benzodiazepine, zopiclone or zolpidem) use within the past month, including prescriptions to treat withdrawal symptoms. At follow-up, the cohort reported a reduced rate of past month prescribed sedative use (23% P 0.99 for change from baseline). At baseline, 40% of participants were prescribed an antidepressant and 13% an antipsychotic medication, which remained similar at follow-up (45% and 13%, respectively). The high level of prescribed sedative drug use reported by people receiving AOD treatment is a serious public health concern given the increasing incidence of drug overdose deaths in Australia.
Publisher: Cold Spring Harbor Laboratory
Date: 22-09-2020
DOI: 10.1101/2020.09.21.20199133
Abstract: The COVID-19 pandemic has impacted people with substance use disorders (SUDs) worldwide and healthcare systems have reorganized their services in response to the pandemic. One week after the announcement of the COVID-19 as a pandemic, in a global survey, 177 addiction medicine professionals described COVID-19-related health responses in their own 77 countries in terms of SUD treatment and harm reduction services. The health response is categorized around (1) managerial measures and systems, (2) logistics, (3) service providers and (4) vulnerable groups. Respondents from over 88% of countries reported that core medical and psychiatric care for SUDs had continued however, only 56% of countries reported having had any business continuity plan, and, 37.5% of countries reported shortages of methadone or buprenorphine supplies. Participants of 41% of countries reported partial discontinuation of harm-reduction services such as needle and syringe programs and condom distribution. 57% of overdose prevention interventions and 81% of outreach services also having been negatively impacted. Participants reported that SUD treatment and harm reduction services had been significantly impacted globally early during the COVID-19 pandemic. Based on our findings, we provide a series of recommendations to support countries to be prepared more efficiently for future waves or similar pandemics to 1) help policymakers generate business continuity plans, 2) maintain use of evidence-based interventions for people with SUDs, 3) be prepared for adequate medication supplies, 4) integrate harm reduction programs with other treatment modalities and 5) have specific considerations for vulnerable groups such as immigrants and refugees. COVID-19 negatively impacted services for PWSUD globally. Addiction medicine downgraded more than other psychiatry services. Business continuity plan for PWSUD services reported only in about half of the countries. Refugees & migrants had more negative impact compared to other vulnerable groups. Harm reduction services discontinued partially or totally during pandemic.
Publisher: SAGE Publications
Date: 10-07-2016
Abstract: There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression. This paper reviews whether current evidence supports the use of ketamine for the clinical treatment of depression. Clinical trials have investigated the use of intravenous ketamine for the treatment of depressive symptoms over the past 15 years. However, there remain many unanswered questions regarding its effectiveness, safety, and the route, dose and regimen for repeated administration. Experts have also raised concerns regarding ketamine’s adverse effects, abuse potential and the risk of addiction. At this stage, the use of ketamine in the treatment of depression remains in the realm of research settings.
Publisher: Frontiers Media SA
Date: 23-12-2019
Publisher: Wiley
Date: 13-06-2020
DOI: 10.1111/ADB.12776
Publisher: Royal College of Psychiatrists
Date: 24-02-2022
DOI: 10.1192/BJI.2022.1
Abstract: The COVID-19 pandemic has significantly affected treatment services for people with substance use disorders (SUDs). Based on the perspectives of service providers from eight countries, we discuss the impact of the pandemic on SUD treatment services. Although many countries quickly adapted in provision of harm reduction services by changes in policy and service delivery, some went into a forced abstinence-based strategy. Similarly, disruption of abstinence-based approaches such as therapeutic communities has been reported. Global awareness is crucial for responsible management of SUDs during the pandemic, and the development of international health policy guidelines is an urgent need in this area.
Publisher: Magnolia Press
Date: 23-11-2016
DOI: 10.11646/ZOOTAXA.4196.3.9
Abstract: The question whether taxonomic descriptions naming new animal species without type specimen(s) deposited in collections should be accepted for publication by scientific journals and allowed by the Code has already been discussed in Zootaxa (Dubois & Nemésio 2007 Donegan 2008, 2009 Nemésio 2009a–b Dubois 2009 Gentile & Snell 2009 Minelli 2009 Cianferoni & Bartolozzi 2016 Amorim et al. 2016). This question was again raised in a letter supported by 35 signatories published in the journal Nature (Pape et al. 2016) on 15 September 2016. On 25 September 2016, the following rebuttal (strictly limited to 300 words as per the editorial rules of Nature) was submitted to Nature, which on 18 October 2016 refused to publish it. As we think this problem is a very important one for zoological taxonomy, this text is published here exactly as submitted to Nature, followed by the list of the 493 taxonomists and collection-based researchers who signed it in the short time span from 20 September to 6 October 2016.
Publisher: Emerald
Date: 12-05-2020
DOI: 10.1108/ECAM-07-2019-0353
Abstract: The purpose of this research is to seek better relational strategies between formal and informal stakeholder relationships to improve megaproject performance. The conceptual model was developed with twenty hypotheses based on the literature review. Then a questionnaire survey was conducted, and the collected data were analyzed by Partial Least squares Structural Equation Modeling (PLS-SEM) for validating the proposed model. Finally, the findings were discussed by a comparative study to explain the different effects of the formal and informal relationship on megaproject performance, and the managerial implications are presented for the stakeholders to implement the relationship management in the megaprojects. The research finding reveals that formal relationship plays a dominating role in cost, quality, and labor protection meanwhile, it is still more reliable in improving coordination, safety and environmental protection. Both formal and informal relationship is equally important towards collaboration and scheduling while the informal relationship is more effective in communication and project transparency. The study extends the knowledge of relationship management in the domain of the megaproject performance. It provides a comprehensive and systematic understanding of the impact of formal and informal stakeholder relationships on ten aspects of the megaproject performance by the proposed conceptual model and PLS-SEM results. The research findings contribute to the theory of relationship management on how the different influences between formal and informal stakeholder relationships lead to better megaproject performance from inter-organizational level to project and societal level.
Publisher: SAGE Publications
Date: 13-09-2023
Publisher: Wiley
Date: 22-01-2019
DOI: 10.1111/ADD.14495
Publisher: SAGE Publications
Date: 12-10-2023
Publisher: SAGE Publications
Date: 07-05-2015
No related grants have been discovered for Shalini Arunogiri.